PodParley PodParley
PodParley
Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis, Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) Trials episode artwork

EPISODE · Dec 13, 2022 · 1H 6M

Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis, Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) Trials

from American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) · host AANEM

Dr. Elie Naddaf, MD interviews Dr. James Howard, MD about the use of complement and the neonatal Fc receptor inhibitors in myasthenia gravis, highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials.

Episode metadata supplied by the publisher feed · Published Dec 13, 2022

Embed this episode

NOW PLAYING

Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis, Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) Trials

0:00 1:06:51

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)?

This episode is 1 hour and 6 minutes long.

When was this American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) episode published?

This episode was published on December 13, 2022.

Can I download this American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!